The oncology assay is the first from Roche using either plasma or tumor tissue samples and identifies 42 mutations in the EGFR gene.
The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.
The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.
The pipeline, called IMPACT, pinpointed genetic variants in lung cancer and melanoma patients and matched them to targeted drugs.
The pharmaceutical giant is aggressively incorporating the gene manipulating tech, especially in target validation and improving disease models.
The Cobas EGFR Mutation Test v2 is Roche's first that can be used with plasma or tissue as a sample type and identifies 42 mutations in the EGFR gene.
Non-small cell lung cancer patients with EGFR mutations now have three treatment choices, and AstraZeneca is working on newer personalized treatment options.
The test was approved for use with Iressa to determine those patients who would benefit by being treated with the drug.
The group used next-generation sequencing and droplet-digital PCR blood-based assays to monitor resistance mutations in colorectal cancer patients.
The draft document, which includes recommendations on which molecular tests labs should perform, on what samples, and with what analytical specifications, is available for comment until April 22.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.